Canaccord Genuity


Canaccord Reiterates Upbeat View of Gran Tierra Energy Inc. Following Second Quarter Results

In a research report released today, Canaccord analyst Christopher Brown reiterated a Buy rating on Gran Tierra Energy Inc. (NYSE:GTE), after the energy company released …

Analysts Remain Bullish Following Glu Mobile Inc. (GLUU) Q2 Earnings

Glu Mobile Inc. (NASDAQ: GLUU), a publisher of mobile games for smartphone and tablet devices, released its Q2 fiscal 2015 earnings on August …

Canaccord Slashes Price Target for Sunshine Heart Inc, But Remains Positive

In a research report released today, Canaccord analyst Jason Mills reiterated a Buy rating on shares of Sunshine Heart Inc (NASDAQ:SSH), but reduced the price …

Canaccord Suggests Stratasys, Ltd. Investors to Remain on the Sidelines

Ahead of the closing bell, Stratasys, Ltd. (NASDAQ:SSYS) shares are falling more than 10% to $32.

Canaccord Bullish on Nokia Corporation (ADR) Following ‘Strong’ 2Q:15 Results

Canaccord Genuity analyst Michael Walkley weighed in today with a favorable report on Nokia Corporation (ADR) (NYSE:NOK), after the company reported second-quarter results above Walkley and consensus …

Canaccord Cuts Price Target for Qorvo Inc on Back of Weak Guidance

Qorvo Inc (NASDAQ:QRVO) shares are tumbling more than 14% to $60.45 after the company reported soft Q2/F’16 guidance which have been accompanied by weaker than anticipated sales …

Here’s Why Canaccord Raised Price Target For SolarCity Corp (SCTY)

In a research report published Wednesday, Canaccord analyst Jed Dorsheimer reiterated a Buy rating on SolarCity Corp (NASDAQ:SCTY) with a price target of $76, …

Canaccord Offers Commentary on Westport Innovations Inc. (USA) Following 2Q15 Results

In a research report issued yesterday, Canaccord analyst John Quealy maintained a Hold rating on shares of Westport Innovations Inc. (USA) (NASDAQ:WPRT) with a …

Canaccord Reiterates Buy on Regeneron Pharmaceuticals Inc (REGN) Following New Collaboration with Sanofi

In a research report released Tuesday, Canaccord analyst John Newman reiterated a Buy rating on Regeneron Pharmaceuticals Inc (NASDAQ:REGN) with a price target of …

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts